1. The Community shall make arrangements for appropriate safety and potency testing of:
- foot-and-mouth disease virus antigens purchased in 1993 and since then kept as a part of the EU emergency stock,
- foot-and-mouth disease vaccine produced in Turkey and used in a prophylactic vaccination programme which includes vaccination of susceptible animals kept in the area of Turkish Thrace,
- bluetongue vaccines produced outside the European Community and purchased for an emergency stock.
2. The maximum cost of the measures referred to in paragraph 1 shall be up to EUR 430000.
The measures mentioned in Article 1 shall be carried out by the Commission in cooperation with the supplier designated by call for tender.
1. To meet the objectives of Articles 1 and 2 the Commission shall conclude contracts without delay.
2. The Director-General of the Directorate-General for Health and Consumer Protection shall be authorised to sign the contracts on behalf of the European Commission.
This Decision is addressed to the Member States.
Done at Brussels, 18 January 2001.
For the Commission
David Byrne
Member of the Commission
(1) OJ L 224, 18.8.1990, p. 19.
(2) OJ L 160, 26.6.1999, p. 103.
(3) OJ L 368, 31.12.1991, p. 21.
(4) OJ L 301, 24.11.1999, p. 6.
(5) OJ L 280, 13.11.1993, p. 33.
(6) OJ L 269, 11.11.1995, p. 29.
(7) OJ L 16, 21.1.1998, p. 45.
(8) OJ L 95, 15.4.2000, p. 39.
